{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Co-investigator:', 'Agnieszka Dancewicz', 'M.Psych.', 'Department:', 'Oncology', 'E-mail:', 'adancewicz@wim.mil.pl', 'Telephone:', '+48 261817248', 'Page 10 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Clinical Trial Summary', 'TITLE', 'A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of', 'Metastatic Renal Cell Carcinoma (ProSun Study)', 'PRINCIPAL INVESTIGATOR', 'Pawel Chrom, M.D.', 'TRIAL LOCATION', 'Military Institute of Medicine', 'Szaser\u00f3w 128, 04-141 Warsaw, Poland', 'STUDY OBJECTIVES', 'Primary objective: To assess an effectiveness of therapy with', 'propranolol plus sunitinib in terms of objective response rate in', 'patients with metastatic renal cell carcinoma.', 'Secondary objectives: To assess the following outcomes: overall', 'survival, progression-free survival, disease control rate, incidence and', 'severity of adverse events, changes from baseline in vital signs and', 'laboratory results, health-related quality of life, disease-related stress,', 'characterization of relationship between the primary tumour tissue', 'and serum biomarkers with treatment and clinical outcomes.', 'STUDY DESIGN', 'It is a single-arm, single-center, open-label, phase II study. Eligible', 'patients will be included in the single investigational cohort treated', 'with:', '- oral sunitinib at a starting dose of 50 mg once daily in 6-weeks cycles', 'consisting of 4 weeks of treatment followed by 2 weeks off the drug,', '- oral propranolol at a starting dose of 40 mg two times daily to a', 'maximum dose of 240 mg a day', 'Physical examination, laboratory findings, electrocardiography and', 'filling health-related quality of life and disease-related stress', 'questionnaires will take place every 6 weeks; computed', 'tomography/magnetic resonance imaging scan will be performed', 'every 12 weeks. The study treatment will last until disease', 'progression, unacceptable toxicity or withdrawal of consent. Each', 'patient will have a summary visit at the time of discontinuation from', 'study treatment. The postdiscontinuation period will continue until', 'death or the end of study data collection.', 'STUDY POPULATION', 'Main inclusion criteria:', '1. Histological diagnosis of clear-cell renal cell carcinoma or mixed-', 'type renal cell carcinoma with more than 60% of clear-cell component', 'in the primary tumor.', '2. Diagnosis of stage IV renal cell carcinoma (primary metastatic or', 'recurrence after surgical procedure).', '3. Prior nephrectomy (complete or partial).', '4. Presence of measurable disease.', '5. Karnofsky performance status: 80-100%.', '6. Favorable or intermediate risk according to Memorial Sloan-', 'Page 11 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Kettering Cancer Center Score.', '7. Adequate organ function, including the following:', '- hepatic: total bilirubin < 2 times the upper limit of normal (excluding', 'patients with Gilbert syndrome), AST and ALT < 5 times the upper limit', 'of normal,', '- renal: serum creatinine < 2 times the upper limit of normal,', '- bone marrow: absolute neutrophil count 1500/mm\u00b3, platelets', '100000/mm\u00b3, hemoglobin 9,5 g/dl.', '8. Normal thyroid function (natural or with supplementation of thyroid', 'hormones).', '9. Age 18 years.', '10. Written informed consent prior to study entry.', 'Main exclusion criteria:', '1. Prior systemic therapy of renal cell carcinoma.', '2. Treatment with propranolol within 6 months of study entry.', '3. Metastases in the central nervous system (patients who had brain', 'metastases that were surgically resected or treated with radiotherapy', 'in the past and now are without neurological symptoms, are allowed', 'on protocol).', '4. Female patients who are pregnant or breast feeding.', '5. Presence of other malignancies (patients with carcinoma in situ of', 'the cervix or basal cell carcinoma of the skin are allowed on protocol).', '6. Presence of any severe and/or uncontrolled medical conditions.', '7. Presence of any contraindication to propranolol.', 'Expected number of', 'patients:', '33', 'INVESTIGATIONAL', 'PRODUCTS', 'Formulations:', 'Tablets for oral administration, containing:', '-', 'sunitinib: 50 mg, 37,5 mg, 25 mg, or 12,5 mg:', '-', 'propranolol: 40 mg', 'STATISTICAL', 'The optimal two-stage Simon design.', 'CONSIDERATIONS', 'Under the conditions of: a level of 0.050, \u00df level of 0.200, the increase', 'in objective response rate from 0.30 for sunitinib monotherapy to 0.55', 'for propranolol plus sunitinib combination, a minimum of 15 patients', 'will be included in the first stage. The trial will be terminated if 6 or', 'fewer patients achieve objective response rate. If the trial goes on to', 'the second stage, a total of 33 patients will be studied. If the total', 'number of patients achieving objective response rate is less than or', 'equal to 13, the combination is rejected.', 'Page 12 of 60']\n\n###\n\n", "completion": "END"}